Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

MNOV – Medicinova Inc

MediciNova, Inc.
MNOV
$1.41
Name : MediciNova, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $69,155,144.00
EPSttm : -0.23
finviz dynamic chart for MNOV
MediciNova, Inc.
$1.41
1.43%
$0.0199

Float Short %

0.39

Margin Of Safety %

Put/Call OI Ratio

0.07

EPS Next Q Diff

EPS Last/This Y

-0.27

EPS This/Next Y

0.12

Price

1.41

Target Price

9

Analyst Recom

1

Performance Q

-11.32

Relative Volume

0.46

Beta

0.41

Ticker: MNOV




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-08MNOV1.49N/AN/A0
2025-05-09MNOV1.480.070.00140
2025-05-12MNOV1.440.070.00140
2025-05-13MNOV1.45580.060.00150
2025-05-14MNOV1.360.060.00160
2025-05-15MNOV1.380.060.00161
2025-05-16MNOV1.320.060.00161
2025-05-19MNOV1.390.060.00161
2025-05-20MNOV1.370.060.00161
2025-05-21MNOV1.39660.230.1048
2025-05-22MNOV1.43210.230.1048
2025-05-23MNOV1.380.230.1048
2025-05-27MNOV1.440.200.0053
2025-05-28MNOV1.42260.200.0053
2025-05-29MNOV1.40.170.0063
2025-05-30MNOV1.410.070.00143
2025-06-02MNOV1.40930.070.00143
2025-06-03MNOV1.440.070.00143
2025-06-04MNOV1.420.070.00143
2025-06-05MNOV1.40.070.00143
2025-06-06MNOV1.420.070.00143
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-08MNOV1.49- - -0.50
2025-05-09MNOV1.47- - -0.50
2025-05-12MNOV1.44- - -0.50
2025-05-13MNOV1.46- - -0.50
2025-05-14MNOV1.36- - -0.50
2025-05-15MNOV1.38- - -0.50
2025-05-16MNOV1.36- - -0.50
2025-05-19MNOV1.40- - -0.50
2025-05-20MNOV1.37- - -0.50
2025-05-21MNOV1.39- - -0.50
2025-05-22MNOV1.38- - -0.50
2025-05-23MNOV1.38- - -0.50
2025-05-27MNOV1.43- - -0.50
2025-05-28MNOV1.40- - -0.50
2025-05-29MNOV1.38- - -0.50
2025-05-30MNOV1.39- - -0.50
2025-06-02MNOV1.41- - -0.50
2025-06-03MNOV1.41- - -0.50
2025-06-04MNOV1.43- - -0.50
2025-06-05MNOV1.39- - -0.50
2025-06-06MNOV1.41- - -0.50
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-08MNOV0.006.080.41
2025-05-09MNOV0.006.080.41
2025-05-12MNOV0.003.560.41
2025-05-13MNOV0.003.560.41
2025-05-14MNOV0.003.560.41
2025-05-15MNOV0.003.560.41
2025-05-16MNOV0.003.560.41
2025-05-19MNOV0.004.570.41
2025-05-20MNOV0.004.570.41
2025-05-21MNOV0.004.570.41
2025-05-22MNOV0.004.570.41
2025-05-23MNOV0.004.570.41
2025-05-27MNOV0.00-0.550.41
2025-05-28MNOV0.00-0.550.39
2025-05-29MNOV0.00-0.550.39
2025-05-30MNOV0.00-0.550.39
2025-06-02MNOV0.00-0.550.39
2025-06-03MNOV0.00-0.550.39
2025-06-04MNOV0.00-0.550.39
2025-06-05MNOV0.00-0.550.39
2025-06-06MNOV0.00-0.550.39
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.12

Avg. EPS Est. Next Quarter

-0.12

Insider Transactions

Institutional Transactions

-0.55

Beta

0.41

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

12

Growth Score

21

Sentiment Score

48

Actual DrawDown %

89.3

Max Drawdown 5-Year %

-89.7

Target Price

9

P/E

Forward P/E

PEG

P/S

P/B

1.39

P/Free Cash Flow

EPS

-0.23

Average EPS Est. Cur. Y​

-0.5

EPS Next Y. (Est.)

-0.38

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.46

Return on Equity vs Sector %

-46.4

Return on Equity vs Industry %

-28.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

MediciNova, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 13
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
stock quote shares MNOV – Medicinova Inc Stock Price stock today
news today MNOV – Medicinova Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MNOV – Medicinova Inc yahoo finance google finance
stock history MNOV – Medicinova Inc invest stock market
stock prices MNOV premarket after hours
ticker MNOV fair value insiders trading